|

BMS-986393 Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Arlo-cel, Arlocabtagene autoleucel, CC-95266, arlo-cel

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2

Indications

  • Cancer2
  • Relapsed or Refractory Multiple Myeloma (RRMM)1
  • Multiple Myeloma1

Birmingham, Alabama2 trials

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.